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Abstract
Acetaminophen can adversely affect the liver especially when overdosed. We used whole blood as 
a surrogate to identify genes as potential early indicators of an acetaminophen-induced response. 
In a clinical study, healthy human subjects were dosed daily with 4g of either acetaminophen or 
placebo pills for 7 days and evaluated over the course of 14 days. Alanine aminotransferase (ALT) 
levels for responders to acetaminophen increased between days 4 and 9 after dosing and 12 genes 
were detected with expression profiles significantly altered within 24 hrs. The early responsive 
genes separated the subjects by class and dose period. In addition, the genes clustered patients who 
overdosed on acetaminophen apart from controls and also predicted the exposure classifications 
with 100% accuracy. The responsive genes serve as early indicators of an acetaminophen exposure 
and their gene expression profiles can potentially be evaluated as molecular indicators for further 
consideration.
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Introduction
Acetaminophen (Tylenol®) is widely used to relieve pain and reduce fever. Currently, the 
maximum U.S. FDA approved daily dose is 4g. Acetaminophen poisoning is common 
world-wide and is potentially fatal 1. The majority of clinical cases present in the emergency 
room with acute liver failure. Previously, the Centers for Disease Control and Prevention and 
the U.S. FDA indicated that about 55 000 to 80 000 people in the U.S. overdose from 
acetaminophen each year, of which at least 500 die particularly from liver failure 2–6. The 
U.S. FDA has issued a warning for manufactures of acetaminophen to indicate the potential 
risk of sudden liver failure. More recently, the manufacture of Tylenol®, an over-the-counter 
product, has included a warning on the label that the drug content contains acetaminophen. 
Physicians have been asked by the U.S. FDA to avoid prescribing pharmaceuticals with a 
high dose of acetaminophen as drug-induced liver failure is a growing concern 7, 8.
The early detection of acetaminophen liver injury and determination of prognosis at 
presentation are critical to clinicians but can be challenging when using serum enzymes as 
an indicator of liver damage 9. Liver biopsies to obtain material for histopathological 
evaluations are invasive and are a significant risk to the patient. Furthermore, at times serum 
acetaminophen levels shortly after overdose are undetectable 10. Thus, there is a need for 
novel diagnostic and prognostic indicators using biospecimens that can be easily obtained 
with minimal invasion and are efficient at early detection.
We used blood as a surrogate to identify gene expression profiles as potential early 
indicators of an acetaminophen response. In a clinical study, “Responders” to dosing of 
acetaminophen were classified apart from “non-responders” based on both ALT levels 
greater than 2x the upper limit of normal and 2x their individual baseline ALT values. We 
detected 12 genes in the blood with expression profiles significantly altered within 24 hrs of 
the beginning of dosing, three days before the responder group’s ALT marker elevated to 
levels that would be classified as responders. Using independent gene expression data from 
the blood of five human acetaminophen overdose patients, the panel of early response genes 
clustered the samples from the overdosed patients apart from controls and also predicted 
exposure to acetaminophen within this independent data set with 100% accuracy. We 
conclude that this panel of blood gene expression profiles can potentially serve as candidates 
for early biomarkers of an acetaminophen response.
Materials and Methods
Study Design
The randomized, single-blind, placebo-controlled, clinical study objective was to identify 
gene expression from whole blood of healthy human subjects receiving 4g of acetaminophen 
daily or placebo that are early indicators of an acetaminophen response, detectable well 
before ALT elevations. Healthy male and female individuals from 18 – 58 years old 
weighing 55 kg to 85 kg volunteered as subjects in the study (See Supplementary Table 1). 
The study was instituted only once. The protocol (#2265) was approved by the University of 
North Carolina-Chapel Hill Institutional Review Board and informed consent was obtained 
from each patient. There were 66 subjects enrolled for 14 days each and were acclimated for 
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3 days on a controlled, standardized whole-food diet in order to assure a uniform nutritional 
intake. Starting on day 0 and until day 7 relative to the start of dosing, each subject received 
daily repeat dosing every 6 hrs (i.e. 4x daily) of either 1g of acetaminophen (two 500-mg 
Tylenol® Extra-Strength tablets, Orth-McNeil Pharmaceuticals, Titusville, NJ, USA) or 
placebo pills orally. Blood was collected at 8 a.m. on each day of the clinical study for ALT 
measurement and complete blood counts (CBC). Furthermore, each day peripheral blood 
(7.5 mls) was drawn into PAXgene™ (PreAnalytiX/QIAGEN, Hilden, Germany) blood 
RNA collection tubes (3 tubes @ 2.5 mls). Samples were mixed and RNA was isolated 
according to the manufacturer’s protocol, including the optional on-column DNase 
digestion. RNA quality was assessed with an Agilent Bioanalyzer™ (Palo Alto, CA) and 
only samples with intact 18S and 28S ribosomal RNA peaks were used for microarray 
analysis. The RNA quality from 3 subjects (#s 1, 2 and 3) were poor and subjects #s 12 and 
21 had no day 0 samples. Therefore, the samples from these subjects were not processed 
further.
Clinical Chemistry
Clinical chemistry evaluations of serum samples were performed using a Roche Cobas Fara 
chemistry analyzer (Roche Diagnostic Systems, Westwood, NJ) to numerically measure 
serum ALT enzyme levels (See Supplementary Table 2).
Classification of Subjects
Individuals given placebos were classified as within the Placebo group. In a randomized 
control trial, elevated levels of serum ALT have been associated with healthy adult human 
subjects receiving 4 g of acetaminophen daily 9. In our study, we classified subjects 
receiving acetaminophen as follows. Responders: Individuals with a 2-fold increase in serum 
ALT (See Supplementary Table 2) from their respective baseline value and greater than 2x 
the upper limit of normal (as defined by historical data from the University of North 
Carolina-Chapel Hill hospital: females = 30 IU/L; males = 40 IU/L) in response to 
acetaminophen. Non-responders: Individuals receiving acetaminophen but not meeting the 
“Responder” criteria. The baseline for normal was defined as the mean of the daily ALT 
measurements obtained in the days before the start of acetaminophen dosing (the 
acclimation period). The baseline ALT levels for subjects #11 and #18 were elevated and 
thus, the data from these subjects were removed from further analysis. The classification 
assignments of the subjects are in Supplementary Table 3.
Microarray Analysis
Gene expression profiling was conducted using Agilent-012097 Human 1A (V2) 
microarrays (Agilent Technologies, Palo Alto, CA). 500 ng of total RNA from a human 
universal reference (Stratagene, La Jolla, CA) and subject samples were amplified using the 
Agilent Low RNA Input Fluorescent Linear Amplification Kit and labeled with Cy3 and 
Cy5 cytofluors respectively according to manufacturer’s protocol. For each two-color 
comparison, 750 ng of each Cy3 and Cy5 cRNA were mixed and fragmented using the 
Agilent In Situ Hybridization Kit protocol. Hybridizations were performed for 17 hrs in a 
rotating hybridization oven according to the Agilent 60-mer oligo microarray processing 
protocol prior to washing and scanning. Gene expression pixel intensities were extracted by 
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scanning the microarrays with an Agilent Scanner (Agilent Technologies, Wilmington, DE). 
The log base 2 pixel intensity values from the Cy3 and Cy5 channels were background 
subtracted, corrected for dye bias and normalized across arrays 11. The preprocessing of the 
data from subjects #s 13, 49 and 63 (Placebo, Non-responder and Responder classes 
respectively) revealed them as being outliers and thus were excluded from further analysis. 
Finally, log base 2 ratio values were generated (subject sample to universal reference) and 
corrected for batch effects (see Supplementary Table 4 for batches) using an empirical Bayes 
model with the classification of the subjects and before or after dosing as covariates and 
parametric estimation of priors12. The microarray data for subject #62 at day -1 and day 4 
and for subject #64 at day -1 were missing and hence these subjects were excluded from 
further analysis. Statistical analysis was performed on the preprocessed data from the 
remaining 54 subjects (Responders n = 12, Non-responders n= 32 and Placebo n= 10).
Statistical Analysis
We used a discontinuous piecewise linear regression (DPLR) model (1st order 
autoregressive process) 13 to analyze the gene expression data by day. The model is similar 
to a classical linear regression. However, with respect to the DPLR model, the regression 
function is in two pieces, separated at the time point at which acetaminophen is 
administered. For each gene, let Yt denote the preprocessed log base 2 ratio value for the tth 
day. The regression model is:
where βo is the Y intercept of the regression line, and where:
When Xt1 ≤ Xp, Xt2 = 0 and Xt3 = 0 as indicator variables, then the response function for the 
regression model becomes βo + β1Xt1 (the 1st piece). Similarly, when Xt1 > Xp, Xt2 = 1 and 
Xt3 = 1 as indicator variables, then the regression model becomes (βo - Xpβ2+ β3)+(β1+ 
β2)Xt1 (the 2nd piece). Thus, if β3 = 0, the piecewise regression is continuous and there is no 
difference in the mean responses for the two regression lines at Xp.
Subject is the random effect in the model and the restricted maximum likelihood (REML) 
method for estimation of variance within each group was used. We assume that the gene 
expression response at different days in the subjects prior to dosing follows a different linear 
relationship after dosing at day Xp (i.e., the linear response is in two pieces) and that the 
linear response may not only change slope at Xp, but may also be discontinuous at Xp. In 
this study, Xp is t = 0 and β3 represents the difference in the mean responses for the two 
regression lines at Xp. For each gene and given the model, we perform a two-sided t-test for 
the null hypothesis Ho: β3 = 0 and reject it for the alternative hypothesis Ha: β3 ≠ 0 at α = 
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0.05. We account for multiple testing of the genes using a false discovery rate (FDR) 14, 15 
q-value ≤ 0.05. Genes with cyclic expression patterns were identified using the sine and 
cosine of X in the following trigonometric model:
where a is the amplitude = 1, 2π/b is the period where b = 1, π = 180, Xt is the day of 
dosing with t = −3, −2, −1, 0, 1, 2, 3, 4, h the horizontal shift = 0 and k is the vertical shift = 
0. Genes with a significant fit to the model (i.e., a correlation coefficient R2 ≥ 0.2) were 
considered cyclic and thus not appropriate for the discontinuous piecewise linear model.
Code availability: The SAS code for the discontinuous piecewise linear regression mixed 
regression model and trigonometric model are available upon request.
Overdosed Patients
Five individuals (2 males and 3 females) of Caucasian or African-American ethnicity who 
overdosed on acetaminophen were admitted to the University of North Carolina-Chapel Hill 
emergency room. The individuals ages ranged from 19 – 59 years, their ALT (U/I) ranged 
between 435 – 6446 and peripheral blood was drawn 2 or 5 days after admittance for 
microarray analysis. Blood was collected using PAXgene vacutainer tubes (PreAnalytiX; 
Qiagen), and RNA was isolated as described by the manufacturer and labeled as described 
above for microarray analysis. Briefly, each sample was hybridized against a human 
universal RNA control (Stratagene, La Jolla, CA) and processed as described above for 
microarray analysis. Hybridizations to Agilent-012097 Human 1A (V2) microarrays 
(Agilent Technologies, Palo Alto, CA) were performed for 17 hrs in a rotating hybridization 
oven according to the Agilent 60-mer oligo microarray processing protocol prior to washing 
and scanning with an Agilent Scanner (Agilent Technologies, Wilmington, DE). The raw 
pixel intensity gene expression data were loaded into the Rosetta Resolver database (build 
5.1.0.1.23, Rosetta Biosoftware, a unit of Rosetta Inpharmatics; Palo Alto, CA) and error 
weighted ratio values computed from the normalized and background-subtracted pixel 
intensity values 16. The log base 10 ratio data were generated as follows. Overdose patients: 
average of baseline group [day -3 human blood] to patient and Baseline group: Reference to 
day -3 human blood.
Predictions
The fold change (samples to universal reference) blood gene expression data of the 12 early 
responsive genes from the placebo and responder subjects in the present study at day 1 (24 
hrs after receiving acetaminophen) were used in a support vector machine 17, 18 (SVM) three 
degrees radial basis gamma kernel to build a predictive model (Partek Genomics Suite v. 6.6, 
St. Louis, MO). Following a comparison of prediction accuracies based on surveying various 
parameter settings and leave-one-out-cross-validation, the parameters with the best accuracy 
were with cost-based shrinking, tolerance of 0.001, nu = 0.5, and gamma = 0.01. The model 
was then applied to the fold change (subject samples to universal reference) blood gene 
expression data of the 12 early responsive genes from the five acetaminophen overdose 
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patients and three controls. Prediction accuracy was based on the number of subjects 
predicted correctly (control as Placebo and overdosed as Responder).
Gene Interaction Analysis
Ingenuity Pathway Analysis (IPA) software build 355958M (Qiagen, Redwood City, CA) 
was used to create a gene interaction network from 9 of the 12 early responsive genes (focus 
genes) detected in the responders only and that were mapped to pathways in the IPA 
knowledgebase content version 21901358. The network was scored according to the –log 
base 10 p-value from a Fisher’s exact test assessing the significance of the proportion of 
highly connected 9 focus genes within, or not in the network to all other genes in the 
knowledgebase within, or not in the network. Finally, the network was pruned to highlight 
the interactions of the focus genes with the central hub.
Results
A Subset of Subjects Respond to Acetaminophen
Fifty-four male and female human subjects (Table 1) were evaluated over the course of a 14 
day acetaminophen response clinical study to monitor changes in serum enzyme levels and 
profile gene expression from their blood. As illustrated in Figure 1, starting on day 0 and 
until day 7, subjects received daily, repeated (4x) dosing of either 1g of acetaminophen or 
placebo pills. As shown in Figure 2a, the ALT levels for the responders to acetaminophen 
are at baseline level between day 0 and 3, they increase between day 3 and 6, and then peak 
between day 7 and 10.
Identification of an Early Gene Expression Response to Dosing
To identify gene expression profiles from the blood of the subjects that respond early during 
the dosing period, we used a discontinuous piecewise regression (Figure 2b) to model the 
data from the subjects between day -3 and day 0 separately from day 1 to day 4 and detect a 
significant change in gene expression. If there is no expression response of a particular gene 
following a subject receiving acetaminophen, then there would be no statistically significant 
difference between the expression of the gene during the acclimation period and the dosing 
period. As displayed in the Venn diagram in Figure 3a, the Placebo and the “Non-responder” 
classes has 48 and 754 genes (1101 probes) respectively with significant differences (FDR ≤ 
0.05) in their gene expression profiles between the two periods whereas the “Responder” 
class has 54 genes significantly different (FDR ≤ 0.05) and responded to the dosing within 
24 hrs. Nine genes overlap between the three classes, but 12 genes are unique to responder 
class (Table 2). The greater number of genes detected from the Non-responders is primarily 
due to the larger sample size for that class. Hence, there is more power of detection to 
identify genes with significant differences between their expression during the acclimation 
period and the dosing period.
We then used principal component analysis (PCA) of the gene expression data to reduce the 
dimension of the 12 genes down to the top two principal components (PCs) that capture the 
majority of variability in the data. Plotting the data with these PCs allows for the projection 
of the samples in two dimensional space and interpretation of the proximity of them to one 
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another. The 12 genes from the Responder class separate the acclimation period from the 
dosing period within each class (Figure 3b). Subjecting the expression data from the 12 
genes to hierarchical clustering, groups the genes that responds similarly across the time 
points and reveals shared expression patterns amongst the samples. These 12 genes 
represented the classes relatively well as depicted by the gene expression patterns in the heat 
map (Figure 4a). Of the 12 early responsive genes specific to the Responder class, five 
decrease in expression 24 hrs after dosing and seven increase in expression (Table 2 and 
Figure 4b).
Early Responsive Genes Discern and Predict Exposure to Acetaminophen
To validate the 12 early responsive genes, we used the gene expression from them to cluster 
five acetaminophen overdose patients and controls from an independent gene expression 
data set according to exposure status. As shown in Figure 4c, the 12 genes cluster the 
overdosed patients together, yet apart from the controls essentially from three groups of 
moderately correlated genes (R > 0.6). All overdose patients presented with elevated ALT 
levels and four of the five with an estimated ingestion of acetaminophen greater than the 
maximum U.S. FDA approved daily dose of 4g (Table 3). However, only one had a blood 
serum acetaminophen level greater than 25 mcg/mL. In addition, using a SVM prediction 
model built from the 12 early responsive genes from the Placebo and Responder subjects in 
the present study at day 1 (24 hrs after receiving acetaminophen), prediction accuracy of the 
exposure status of the overdose patients and controls was 100% (Table 4).
Molecular Interactions and Pathways Associated with the Acetaminophen Early Response
Using 9 of the 12 early response genes detected in the Responders that were mapped in the 
IPA canonical pathway database, we found a molecular interaction of interest with a score 
=26 (p-value = 1x10-26). As shown in Figure 5, several of these dysregulated early response 
genes are associated with ubiquitin C (UBC) as the central hub and three interact with 
interleukin 4 (IL4).
Discussion
Previously, the Centers for Disease Control and Prevention and the FDA indicated that about 
55 000 to 80 000 people in the U.S. overdose from acetaminophen each year of which at 
least 500 die particularly from liver failure 2–6. The U.S. FDA has issued a warning for 
manufactures of acetaminophen to indicate the potential risk of sudden liver failure and 
more recently the manufacture of Tylenol®, an over-the-counter product, has included a 
warning on the label that the drug content contains acetaminophen. We sought to use blood 
as a surrogate tissue in order to identify gene expression profiles derived from blood cells as 
early indicators of an acetaminophen response in other tissues.
Based on microarray gene expression data we identified 54 genes, 12 which are unique to 
the Responder group, that were significantly differentially expressed as early as 24 hrs 
subsequent to dosing with acetaminophen. Using the 12 early responsive genes, we could 
differentiate the samples of subjects within the acclimation period from those in the dosing 
period. In addition, they allowed us to separately cluster Responder, Non-responder and 
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Placebo subjects distinctly from each other and also allowed for the separate clustering of 
subjects who overdosed on acetaminophen from controls. Furthermore, against an 
independent human blood gene expression data set, the early responsive genes allowed us to 
predict the acetaminophen overdosed exposure samples and control samples with 100% 
accuracy.
Of the 12 early responder genes, several have been reported to be associated with the 
immune system or cell division and some code for zinc finger binding proteins or complexes 
in the endoplasmic reticulum. In published studies, five of these genes have been shown to 
be differentially expressed in rodents following acetaminophen exposure 19–22. Early 
consequences of acetaminophen intoxication in rats revealed structural changes of the liver 
cells and dilatation of the endoplasmic reticulum 23 as well as damage to mitochondria 20. 
KDELC1 encodes a protein that is localized to the lumen of the endoplasmic reticulum 24 
whereas SLC35E encodes a multiple spanning domain protein which transports nucleotide-
sugar (a substrate for glycosyltransferases) from the cytosol to the lumen of the Golgi 
apparatus and endoplasmic reticulum 25. Interestingly, zinc finger and BTB domain 
containing 16 (ZBTB16) is associated with increase of the mitochondria membrane potential 
26
 and integrin-beta 2 (ITGB2), which encodes CD18, has been shown to be associated with 
increased liver damage 27.
Exposure to a toxic dose of acetaminophen leads to an inflammatory/immune response that 
consists of a release of cytokines/chemokines as well as an innate immune cell infiltration in 
the liver 28–31 in addition to hepatocyte damage. Our IPA analysis of the 12 early response 
“predictor” genes revealed potential molecular interactions between 9 of these genes with 
ubiquitin C (UBC), a stress response gene 32. This potential interaction may be suggestive of 
an early cellular repair response to acetaminophen exposure. Toxic stress can cause protein 
misfolding and the accumulation of misfolded proteins in the endoplasmic reticulum leading 
to ubiquitination of these macromolecules 33–35. UBC is involved with ubiquitination and is 
associated with protein degradation, DNA repair and cell cycle regulation 32. CCNA2, which 
produces cyclin-A2, regulates cell cycle progression, cell division and cell proliferation. The 
induction of this gene in the Responders to acetaminophen may be associated with a signal 
to proliferate in response to acetaminophen-induced cell death 34. Finally, ITGB2 plays a 
role in the immune response and it has been shown that neutrophil chemotaxis correlates 
significantly with liver necrosis from acetaminophen toxicity 19.
Our findings support the hypothesis that blood gene expression profiles can serve as 
candidates for early biomarkers of an acetaminophen-induced response. Due to the small 
sample size of the test data set, the predictive value of the 12 early responder genes should 
be interpreted with caution. Further studies to evaluate the performance of the predictive 
genes are needed as resources and clinical samples become available.
Other mechanistic biomarkers for acetaminophen toxicity have been investigated 36–41. 
Genes and their expression as early biomarkers of an adverse acetaminophen response have 
some advantages in that they are mostly well-annotated, they are protein-coding and harbor 
the genetic code of variants, and they have relationships with each other in a systems/gene 
network manner. Furthermore, gene expression assays are typically more robust and 
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reproducible than proteomic and metabolomics assays albeit they can be more laborious and 
costly to implement. We anticipate that as with FDA-approved microarray-based clinical 
screens for determination of how a person metabolizes medicines or the assessment of risk 
that a breast tumor will metastasize, a diagnostic gene expression assay using genomic 
biomarkers for early detection of acetaminophen exposure is quite plausible for translation 
to clinical practice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This research was supported [in part] by the Intramural Research Program of the National Institute of 
Environmental Health Sciences, NIH, and National Institute of Environmental Health Sciences grant P30ES10126, 
NIH grants R37 GM38149 and K23 RR21857-01, and The University of North Carolina General Clinical Research 
Center grant M000046.
References
1. Ferner RE, Dear JW, Bateman DN. Management of paracetamol poisoning. BMJ. 2011; 342:d2218. 
[PubMed: 21508044] 
2. Manthripragada AD, Zhou EH, Budnitz DS, Lovegrove MC, Willy ME. Characterization of 
acetaminophen overdose-related emergency department visits and hospitalizations in the United 
States. Pharmacoepidemiol Drug Saf. 2011; 20(8):819–826. [PubMed: 21294217] 
3. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced 
acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005; 
42(6):1364–1372. [PubMed: 16317692] 
4. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated 
overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006; 15(6):398–405. [PubMed: 
16294364] 
5. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a 
prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern 
Med. 2002; 137(12):947–954. [PubMed: 12484709] 
6. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report 
of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th 
Annual Report. Clin Toxicol (Phila). 2009; 47(10):911–1084. [PubMed: 20028214] 
7. Mitka M. FDA asks physicians to stop prescribing high-dose acetaminophen products. JAMA. 2014; 
311(6):563. [PubMed: 24519283] 
8. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. 
JAMA. 2009; 302(4):369–371. [PubMed: 19622807] 
9. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. 
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a 
randomized controlled trial. JAMA. 2006; 296(1):87–93. [PubMed: 16820551] 
10. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008; 359(3):285–292. 
[PubMed: 18635433] 
11. Chou JW, Paules RS, Bushel PR. Systematic variation normalization in microarray data to get gene 
expression comparison unbiased. J Bioinform Comput Biol. 2005; 3(2):225–241. [PubMed: 
15852502] 
12. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using 
empirical Bayes methods. Biostatistics. 2007; 8(1):118–127. [PubMed: 16632515] 
13. Neter, J., Kutner, MH., Nachtsheim, CJ., Wasserman, W. Applied linear statistical models. 4. Vol. 
xv. Irwin; Chicago: 1996. p. 720
Bushel et al. Page 9
Pharmacogenomics J. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Storey JD. A direct approach to false discovery rates. Journal of the Royal Statistical Society Series 
B-Statistical Methodology. 2002; 64:479–498.
15. Storey JD. The positive false discovery rate: A Bayesian interpretation and the q-value. Annals of 
Statistics. 2003; 31(6):2013–2035.
16. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, et al. Functional 
discovery via a compendium of expression profiles. Cell. 2000; 102(1):109–126. [PubMed: 
10929718] 
17. Hastie, T., Hastie, T., Tibshirani, R., Friedman, JH. The elements of statistical learning : data 
mining, inference, and prediction. Vol. xvi. Springer; New York: 2001. p. 533
18. Omer A, Singh P, Yadav NK, Singh RK. An overview of data mining algorithms in drug induced 
toxicity prediction. Mini Rev Med Chem. 2014; 14(4):345–354. [PubMed: 24552264] 
19. Beyer RP, Fry RC, Lasarev MR, McConnachie LA, Meira LB, Palmer VS, et al. Multicenter study 
of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic 
analyses. Toxicol Sci. 2007; 99(1):326–337. [PubMed: 17562736] 
20. Heinloth AN, Boorman GA, Foley JF, Flagler ND, Paules RS. Gene expression analysis offers 
unique advantages to histopathology in liver biopsy evaluations. Toxicol Pathol. 2007; 35(2):276–
283. [PubMed: 17366322] 
21. Baken KA, Pennings JL, Jonker MJ, Schaap MM, de Vries A, van Steeg H, et al. Overlapping gene 
expression profiles of model compounds provide opportunities for immunotoxicity screening. 
Toxicol Appl Pharmacol. 2008; 226(1):46–59. [PubMed: 17942131] 
22. Bushel, PR. PhD dissertation. 2005. Clustering of Mixed Data Types with Application to 
Toxicogenomics. 
23. Poulsen HE, Petersen P, Vilstrup H. Quantitative liver function and morphology after paracetamol 
administration to rats. Eur J Clin Invest. 1981; 11(3):161–164. [PubMed: 6791935] 
24. Lewis MJ, Pelham HR. Ligand-induced redistribution of a human KDEL receptor from the Golgi 
complex to the endoplasmic reticulum. Cell. 1992; 68(2):353–364. [PubMed: 1310258] 
25. Handford M, Rodriguez-Furlan C, Orellana A. Nucleotide-sugar transporters: structure, function 
and roles in vivo. Braz J Med Biol Res. 2006; 39(9):1149–1158. [PubMed: 16981043] 
26. Parrado A, Robledo M, Moya-Quiles MR, Marin LA, Chomienne C, Padua RA, et al. The 
promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the 
proapoptotic BID protein in lymphocytes. Proc Natl Acad Sci U S A. 2004; 101(7):1898–1903. 
[PubMed: 14769944] 
27. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, et al. Chronic active hepatitis in 
transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A. 1994; 91(2):
614–618. [PubMed: 8290572] 
28. Krenkel O, Mossanen JC, Tacke F. Immune mechanisms in acetaminophen-induced acute liver 
failure. Hepatobiliary Surg Nutr. 2014; 3(6):331–343. [PubMed: 25568858] 
29. Liu ZX, Kaplowitz N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert 
Opin Drug Metab Toxicol. 2006; 2(4):493–503. [PubMed: 16859400] 
30. Masson MJ, Peterson RA, Chung CJ, Graf ML, Carpenter LD, Ambroso JL, et al. Lymphocyte loss 
and immunosuppression following acetaminophen-induced hepatotoxicity in mice as a potential 
mechanism of tolerance. Chem Res Toxicol. 2007; 20(1):20–26. [PubMed: 17226923] 
31. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: 
the role of sterile inflammation and innate immunity. Liver Int. 2012; 32(1):8–20. [PubMed: 
21745276] 
32. Radici L, Bianchi M, Crinelli R, Magnani M. Ubiquitin C gene: Structure, function, and 
transcriptional regulation. Advances in Bioscience and Biotechnology. 2013; 4:1057–1062.
33. Nagy G, Kardon T, Wunderlich L, Szarka A, Kiss A, Schaff Z, et al. Acetaminophen induces ER 
dependent signaling in mouse liver. Arch Biochem Biophys. 2007; 459(2):273–279. [PubMed: 
17207453] 
34. McQueen, CA. Comprehensive Toxicology. Elsevier Science & Technology Books; San Diego, 
Saint Louis: 2010. 
35. Yoshida H. ER stress and diseases. FEBS J. 2007; 274(3):630–658. [PubMed: 17288551] 
Bushel et al. Page 10
Pharmacogenomics J. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
36. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, 
potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009; 106(11):
4402–4407. [PubMed: 19246379] 
37. Ward J, Kanchagar C, Veksler-Lublinsky I, Lee RC, McGill MR, Jaeschke H, et al. Circulating 
microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. 
Proc Natl Acad Sci U S A. 2014; 111(33):12169–12174. [PubMed: 25092309] 
38. Kumar BS, Chung BC, Kwon OS, Jung BH. Discovery of common urinary biomarkers for 
hepatotoxicity induced by carbon tetrachloride, acetaminophen and methotrexate by mass 
spectrometry-based metabolomics. J Appl Toxicol. 2012; 32(7):505–520. [PubMed: 22131085] 
39. van Swelm RP, Laarakkers CM, van der Kuur EC, Morava-Kozicz E, Wevers RA, Augustijn KD, et 
al. Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver 
injury using proteomic profiling in mice. PLoS One. 2012; 7(11):e49524. [PubMed: 23166697] 
40. Prot JM, Briffaut AS, Letourneur F, Chafey P, Merlier F, Grandvalet Y, et al. Integrated proteomic 
and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip. PLoS 
One. 2011; 6(8):e21268. [PubMed: 21857903] 
41. Merrick BA, Bruno ME, Madenspacher JH, Wetmore BA, Foley J, Pieper R, et al. Alterations in 
the rat serum proteome during liver injury from acetaminophen exposure. J Pharmacol Exp Ther. 
2006; 318(2):792–802. [PubMed: 16687475] 
Bushel et al. Page 11
Pharmacogenomics J. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Study design. Blood draws from subjects are represented by black arrows. Red arrows 
represent acetaminophen doses. The numbers represent the days relative to the initial dose of 
acetaminophen.
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Figure 2. 
Response to acetaminophen dosing. (a) Plot of alanine aminotransferase (ALT) in IU/L for 
each of the responder subjects at a given day. (b) Discontinuous piecewise regression. 
Representation of the response function for a discontinuous piecewise regression on genes 
expression (y-axis) dependent on the day of blood draw (x-axis). Xp is the jump point 
between the two regression lines and denotes the point at which acetaminophen is given. The 
solid line represents a gene expression response during the acclimation period. The dashed 
line represents an increase in gene expression following dosing of acetaminophen. The 
slanted dotted line represents a decrease in gene expression following dosing of 
acetaminophen.
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Figure 3. 
Overlap of responsive genes and separation of classes. (a) Venn diagram of early responsive 
genes (q-value ≤ 0.05). (b) Principal component analysis showing the separation of classes 
by period based on the average of the 12 mean responsive genes according to class and day. 
The numbers in the data points represent the day relative to the start of dosing. The percent 
of variation captured by each principal component (PC) is denoted on each axis.
Bushel et al. Page 14
Pharmacogenomics J. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Heat maps and clustering of responsive genes and samples. (a) Clustering of the 12 genes 
with change in mean expression following dosing. Cosine correlation dissimilarity with 
Ward clustering was used. The log base 2 gene expression ratio data (subject to reference) 
for subjects within each class at a given day were averaged and then each profile was 
standardized such that the distribution across the days has a mean equal to 0 and standard 
deviation of 1. The days relative to the initial dosing are denoted. The heat map color bar 
represents the relative gene expression: red is up-regulated, blue is down-regulated. (b) Plot 
of the gene expression data by day for the 12 early responsive genes. The x-axis is the day 
relative to the initial day of dosing. The y-axis is the least square (LS) mean of the log base 2 
ratio data (subject to reference). The error bars represent the standard error of the mean. (c) 
Two-dimensional clustering of the 12 genes and subjects overdosed on acetaminophen or 
controls. Cosine correlation dissimilarity with average linkage clustering was used. Log base 
2 ratio data (reference to subject) is represented by color: red is up-regulated, blue is down-
regulated.
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Figure 5. 
Gene interaction network. Using 9 of the 12 early response genes detected in the responders 
that were mapped to pathways in the Ingenuity Pathway Analysis canonical database, 
molecular networks were generated. Colored nodes represent genes that are part of the 12 
early response genes. Red represents increased expression, green, decreased expression. 
Shapes representations: Circles, protein-coding genes; diamond, enzyme; square, cytokine; 
horizontal ovals, transcription regulators; vertical oval, transmembrane receptor. A solid line 
represents a direct interaction whereas a dashed line represents an indirect interaction. A line 
with an arrow denotes activation whereas a line with an arrow and a pipe (|) denotes acts on 
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and inhibits respectively. A line without an arrow or pipe (|) denotes a protein-protein 
interaction.
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Table 1
Demographics of subjects in the clinical study with gene expression measurements.
Classes Number
Placebos: 10
Non-responders 32
Responders: 12
Ethnicities
Caucasian: 20
Hispanic: 23
African American: 10
Asian: 1
Age range (years) 18–58
Genders
Males: 32
Females: 22
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